Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/iid3.400 http://scihub22266oqcxt.onion/10.1002/iid3.400 33465283!8013503!33465283     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Immun+Inflamm+Dis 2021 ; 9 (2): 399-405 Nephropedia Template TP {{tp|p=33465283|t=2021. Efficacy of canakinumab in mild or severe COVID-19 pneumonia |pdf=|usr=}}{{33465283}} gab.com Text Efficacy of canakinumab in mild or severe COVID-19 pneumonia JO: Immun Inflamm Dis http://www.kidney.de/pget.php?&tw=1&pmid=33465283 #FOAvip BACKGROUND: Clinicians all around the world are currently experiencing a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several therapeutic strategies have been used until now but, to date, there is no specific therapy to treat SARS-CoV-2 infection. In this study, we used canakinumab, a human monoclonal antibody targeting interleukin-1 beta to improve respiratory function and laboratory parameters compared with standard therapy (hydroxycloroquine plus lopinavir/ritonavir). METHODS: We enrolled 34 patients with mild or severe non intensive care unit (ICU) coronavirus disease 2019 (COVID-19): 17 patients treated with standard therapy and 17 patients treated with a subcutaneous single dose of canakinumab 300 mg. We collected data about oxygen supports and laboratory parameters such as inflammation indices and hemogasanalysis. We compared the data collected before the administration of canakinumab (T0), 3 days after T0 (T1) and 7 days after T0 (T2) with the same data from patients taking the standard therapy. RESULTS: We observed a reduction in inflammation indices and a significant and rapid increase in P/F ratio in canakinumab group, with improvement of 60.3% after the administration. We reported a significant reduction in oxygen flow in patients treated with canakinumab (-28.6% at T1 vs. T0 and -40.0% at T2 vs. T1). Conversely, the standard group increased the supply of high oxygen at T1 versus T0 (+66.7%), but reduced oxygen flows at T2 versus T1 (-40.0%). CONCLUSION: In hospitalized adult patients with mild or severe non ICU COVID-19, canakinumab could be a valid therapeutic option. Canakinumab therapy causes rapid and long-lasting improvement in oxygenation levels in the absence of any severe adverse events. Twit Text FOAVip Efficacy of canakinumab in mild or severe COVID-19 pneumonia ????Immun Inflamm Dis http://www.kidney.de/pget.php?&tw=1&pmid=33465283 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33465283 #FOAvip English Wikipedia <ref>{{Cite pmid|33465283}}</ref> Efficacy of canakinumab in mild or severe COVID-19 pneumonia #MMPMID33465283 Falasca K; Di Penta M; Ucciferri C; Auricchio A; Di Nicola M; Marchioni M; Celletti E; Sabatini E; Cipollone F; Vecchiet J Immun Inflamm Dis 2021[Jun]; 9 (2): 399-405 PMID33465283show ga BACKGROUND: Clinicians all around the world are currently experiencing a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several therapeutic strategies have been used until now but, to date, there is no specific therapy to treat SARS-CoV-2 infection. In this study, we used canakinumab, a human monoclonal antibody targeting interleukin-1 beta to improve respiratory function and laboratory parameters compared with standard therapy (hydroxycloroquine plus lopinavir/ritonavir). METHODS: We enrolled 34 patients with mild or severe non intensive care unit (ICU) coronavirus disease 2019 (COVID-19): 17 patients treated with standard therapy and 17 patients treated with a subcutaneous single dose of canakinumab 300 mg. We collected data about oxygen supports and laboratory parameters such as inflammation indices and hemogasanalysis. We compared the data collected before the administration of canakinumab (T0), 3 days after T0 (T1) and 7 days after T0 (T2) with the same data from patients taking the standard therapy. RESULTS: We observed a reduction in inflammation indices and a significant and rapid increase in P/F ratio in canakinumab group, with improvement of 60.3% after the administration. We reported a significant reduction in oxygen flow in patients treated with canakinumab (-28.6% at T1 vs. T0 and -40.0% at T2 vs. T1). Conversely, the standard group increased the supply of high oxygen at T1 versus T0 (+66.7%), but reduced oxygen flows at T2 versus T1 (-40.0%). CONCLUSION: In hospitalized adult patients with mild or severe non ICU COVID-19, canakinumab could be a valid therapeutic option. Canakinumab therapy causes rapid and long-lasting improvement in oxygenation levels in the absence of any severe adverse events. |*COVID-19 Drug Treatment[MESH] |*Molecular Targeted Therapy[MESH] |*Pandemics[MESH] |*SARS-CoV-2[MESH] |Aged[MESH] |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH] |Antiviral Agents/therapeutic use[MESH] |COVID-19/blood/therapy[MESH] |Combined Modality Therapy[MESH] |Drug Therapy, Combination[MESH] |Female[MESH] |Humans[MESH] |Hydroxychloroquine/therapeutic use[MESH] |Interleukin-1beta/*antagonists & inhibitors[MESH] |Lopinavir/therapeutic use[MESH] |Male[MESH] |Middle Aged[MESH] |Oxygen Inhalation Therapy[MESH] |Ritonavir/therapeutic use[MESH]Efficacy of canakinumab in mild or severe COVID-19 pneumonia (epmc).pdf DeepDyve Pubget Overpricing